THE 2021
CPCC/UCSF PATIENT CONFERENCE ON PROSTATE CANCER

Presented by The California Prostate Cancer Coalition and the Helen Diller Family Comprehensive Cancer Center, UCSF

May 14-15, 2021 • Virtual Conference
# CPCC/UCSF PATIENT CONFERENCE ON PROSTATE CANCER

**Day One Friday, May 14 (1:00PM-5:00PM PDT)**

## AGENDA

<table>
<thead>
<tr>
<th>Session Name</th>
<th>Time</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>Opening Remarks</td>
<td>1:00 - 1:10</td>
<td>Eric Small, MD, and Merel Nissenberg, Esq.</td>
</tr>
</tbody>
</table>

### I. INTRODUCTION TO PROSTATE CANCER: Session Chair, Felix Feng, MD

1. Prostate Cancer Epidemiology, Screening and Diagnosis | 1:10 - 1:20 | Matthew Cooperberg, MD, MPH |
2. Race, Racism and Prostate Cancer Disparities | 1:20 - 1:30 | Mack Roach III, MD |
3. An Introduction to Clinical Trials | 1:30 - 1:40 | Rahul Aggarwal, MD |

**BREAK** | 1:45 - 1:50 |

### II. LOCALIZED PROSTATE CANCER: Session Chair, Peter Carroll, MD, MPH

4. Risk Stratification | 1:50 - 2:30 | Felix Feng, MD |
5. Treatment Approaches:  
  - Active Surveillance  
  - Surgery  
  - Radiation  
  - ADT | 2:30 - 3:30 | Peter Carroll, MD, MPH; Matthew Cooperberg, MD, MPH; Mack Roach III, MD; Eric Small, MD |

**BREAK** | 3:30 - 3:35 |

6. Localized Prostate Cancer Cases  
  - Decision Making Considerations  
  - Panel Discussion: Localized Prostate Cancer Cases | 3:35 - 4:30 | Stan Rosenfeld  
  **Panel:** Peter Carroll, MD, MPH; Matthew Cooperberg, MD, MPH; Felix Feng, MD; Mack Roach III, MD; Eric Small, MD |

### III. PROSTATE CANCER AND LIFESTYLE: Session Chair, June Chan, ScD

7. Diet and Exercise as Part of Your Prostate Cancer Treatment Plan | 4:30 - 5:00 | June Chan, ScD and Stacey Kenfield, ScD |

**Day Two Saturday, May 15 (9:00AM-12:45PM PDT)**

<table>
<thead>
<tr>
<th>Session Name</th>
<th>Time</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welcome</td>
<td>9:00 - 9:05</td>
<td></td>
</tr>
</tbody>
</table>

### IV. PSA RECURRENT PROSTATE CANCER: Session Chair, Mack Roach, III, MD

8. PSA Recurrence, Risk Assessment | 9:05 - 9:20 | Mack Roach, III, MD |
9. PSMA PET and Functional Imaging | 9:20 - 9:35 | Thomas Hope, MD |
10. Oligometastatic Disease: Metastasis Directed Therapy and SBRT | 9:35 - 9:50 | Felix Feng, MD |
### IV. PSA RECURRENT PROSTATE CANCER: Session Chair, Mack Roach, III, MD

<table>
<thead>
<tr>
<th>Session Name</th>
<th>Time</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>11. Systemic Therapy Options for “PSA Only” Disease</td>
<td>9:50 - 10:05</td>
<td>Rahul Aggarwal, MD</td>
</tr>
</tbody>
</table>
| 12. Panel Discussion: Recurrent Prostate Cancer Cases | 10:05 - 10:55 | Panel Chair: Eric Small, MD  
Panel: Hala Borno, MD; Peter Carroll, MD, MPH; Matthew Cooperberg, MD, MPH; Mack Roach, III, MD; Thomas Hope, MD |

**BREAK** 10:55 - 11:00

### V. ADVANCED PROSTATE CANCER: Session Chair, Eric Small, MD

<table>
<thead>
<tr>
<th>Session Name</th>
<th>Time</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>13. Untreated Metastatic Prostate Cancer</td>
<td>11:00 - 11:15</td>
<td>Rahul Aggarwal, MD</td>
</tr>
<tr>
<td>14. ADT Resistant Non-Metastatic Prostate Cancer (nmCRPC)</td>
<td>11:15 - 11:30</td>
<td>Eric Small, MD</td>
</tr>
<tr>
<td>15. ADT Resistant Metastatic Prostate Cancer (mCRPC): Conventional Therapy</td>
<td>11:30 - 11:45</td>
<td>Hala Borno, MD</td>
</tr>
<tr>
<td>16. Investigational Therapy</td>
<td>11:45 - 12:00</td>
<td>Eric Small, MD</td>
</tr>
</tbody>
</table>

**BREAK** 12:00 - 12:05

**TRANSITION FROM WEBINAR TO ZOOM MEETING FOR BREAKOUTS**

### VI. CONCURRENT MEET-THE-FACULTY BREAKOUT SESSIONS

Conference attendees may drop in to any or all.

- **Hala Borno, MD**: Advanced Disease, Clinical Trials  
  June Chan, ScD: Diet and Exercise  
  Peter Carroll, MD, MPH: Early Stage Disease  
  Matthew Cooperberg, MD, MPH: Early Stage Disease, Genomic Testing  
  Thomas Hope, MD: Imaging  
  Stacey Kenfield, ScD: Diet and Exercise  
  Michael Rabow, MD: Symptom Management (Physical and Emotional) for Patients and Caregivers  
  Stan Rosenfeld: Patient Peer Support, Personal Decision Making  
  Mack Roach III, MD: Early Stage Disease  
  Alan Shindel, MD, MAS: Sexual Function  
  Eric Small, MD: Advanced Disease, Drug Development Trials, Genomic Testing

**CONFERENCE ADJOURNED** 12:45
WELCOME TO THE 2021 CPCC /UCSF
2nd PATIENT CONFERENCE ON
PROSTATE CANCER!
May 14-15, 2021
STEERING COMMITTEE

The California Prostate Cancer Coalition (CPCC) and The Helen Family Diller Comprehensive Cancer Center warmly welcome you to the 2021 Patient Conference on Prostate Cancer, a National Conference intended for patients, families, caregivers, health care professionals and advocates throughout the country. Thank you to UCSF for graciously offering its Parnassus Campus for this Conference.

In January 2017 at the CPCC Face-to-Face Board Meeting in San Francisco, while prioritizing what activities the CPCC Board should plan, it was suggested that CPCC hold a statewide prostate cancer symposium that would take place in California but be open to others across the country. At subsequent Board Calls the idea took hold and it was tentatively envisioned for the first half of 2019.

The 2019 1st Annual CPCC/UCSF Patient Conference on Prostate Cancer was a stunning success. It was videotaped, and that resource has been viewed on the UC YouTube Station over 122,000 times! Now, after a difficult year+ of a pandemic, and many unknowns, we present, virtually, the 2021 2nd Patient Conference on Prostate Cancer, a National Conference for Patients, Families, Caregivers, Health Care Providers and Advocates, with the theme: “Using current and cutting-edge information to help make informed decisions.” Our Faculty is among the best in the nation. The Agenda is strong. We hope you find this Conference valuable and unique, and we are glad that you’re here!

EDUCATIONAL OBJECTIVE

At the conclusion of this Patient Conference on Prostate Cancer, attendees should be aware of the basics of prostate cancer; fundamentals of testing (genetic, genomic and other tests and imaging); fundamentals of treatment for different stages of prostate cancer, including clinical trials; disparities; the importance of a healthy lifestyle (diet, exercise) in addressing prostate cancer; how to manage side effects from diagnosis and treatment; and how to ensure that patients have appropriate access to care for their disease, whether being treated at an academic center or in a community setting. This information should then enable patients - and those that help them make treatment choices - to make informed, individualized decisions with their physicians.
THE CALIFORNIA PROSTATE CANCER COALITION
“Fighting Prostate Cancer in California since 1997”

The California Prostate Cancer Coalition (CPCC) was organized in 1997 as a 501(c)(3) not-for-profit organization, made up of prostate cancer patients, family members, health care providers and other individuals interested in prostate cancer throughout the State of California. We are saving men’s lives and enhancing the quality of life for men and their families!

The Board of the California Prostate Cancer Coalition (CPCC) is composed of individuals from Northern, Central, and Southern California, and it meets monthly with up to two Face-to-Face Meetings each year. CPCC is a Proud Participant in the National Alliance of State Prostate Cancer Coalitions (NASPCC). CPCC President, Merel Nissenberg, also serves as President of NASPCC. CPCC Vice President Tom Kirk also serves as an Invited Member of NASPCC’s Executive Committee.

What does CPCC do as part of its Mission?

- We advocate for the early detection of potentially deadly prostate cancer
- We are making prostate cancer a key health care priority in California
- We network all the prostate cancer support groups in the state
- We disseminate information relating to prostate cancer, including a durable, laminated awareness and education tool. www.prostatecalif.org/patient-guide
- We advocate for prostate cancer legislation and funding and helped make IMPACT for underserved men a permanent California state program
- We advocate for the highest quality of life for prostate cancer patients and their families
- We perform outreach to, and involve all communities
- We publish a newsletter
- We maintain a website: www.prostatecalif.org
- We conduct annual workshops for prostate cancer support groups

CPCC BOARD OF DIRECTORS 2020-2021

Frank Balthis; Arthur “Tony” Blain, MD; Barry Chauser, MD; Marc Dall’Era, MD; William Doss; Joe Ferrara; Earl H. Jones, Jr.; Thomas Kirk (Vice President, Treasurer); Arthur Lurvey, MD; Leonard S. Marks, MD; Jessica Myers-Schecter; Beverly Nicholson; Merel Grey Nissenberg, Esq. (President); Tiffany Razzo (Secretary); Joseph E. Scherger, MD, MPH; and Westley Sholes

For more information: call Merel Nissenberg at 424-253-1168 or send an e-mail to cpcc@prostatecalif.org.

The November 2019 Board Meeting and “Roundtable on Access, Step Therapy, and the IMPACT Program”, with guests
In 1948, the University of California at San Francisco (UCSF) established the Cancer Research Institute, a precursor to consolidation of its cancer activities in more recent decades. NCI designation as a comprehensive cancer center came in 1999 and the Center was renamed the UCSF Helen Diller Family Comprehensive Cancer Center in 2007.

The UCSF Helen Diller Family Comprehensive Cancer Center was the first center in the Bay Area to receive the prestigious designation of “comprehensive” from the National Cancer Institute. The Helen Diller Family Comprehensive Cancer Center treats all forms of cancer. With new facilities, expanded programs and innovative research, it helps cancer patients live longer and fuller lives. UCSF Helen Diller Family Comprehensive Cancer Center is an NCI-designated Cancer Center, affiliated with the UCSF School of Medicine and the UCSF Medical Center. It is one of 69 cancer research institutions in the United States supported by the National Cancer Institute, and one of three in Northern California. The Helen Diller Family Comprehensive Cancer Center provides exceptional patient care at: UCSF Medical Center at Mount Zion, UCSF Medical Center at Mission Bay, UCSF Medical Center at Parnassus, Zuckerberg San Francisco General Hospital, and the San Francisco Veterans Affairs Medical Center.

The UCSF Helen Diller Family Comprehensive Cancer Center combines basic science, clinical research, epidemiology/cancer control and patient care from throughout the University of California, San Francisco system. UCSF’s long tradition of excellence in cancer research includes the Nobel Prize-winning work of J. Michael Bishop and Harold Varmus, who discovered cancer-causing oncogenes. Their work opened new doors for exploring genetic abnormalities that cause cancer, and formed the basis for some of the most important cancer research happening today.

**Basic Scientific Research**
From understanding normal cellular processes to discovering the underlying molecular and genetic causes of cancer when these processes go awry, UCSF researchers are committed to moving scientific insights forward and pursuing their relevance for clinical oncology and cancer prevention.

**Clinical Research**
Clinical scientists explore how a greater understanding of fundamental biological events can be transformed into clinical tools. New forms of cancer treatment, as well as innovations in diagnosis and prognosis, undergo rigorous evaluation for safety and efficacy. This translates into improved patient outcomes and hope for the future.

**Patient Care**
The Helen Diller Family Comprehensive Cancer Center provides exceptional patient care at five San Francisco medical centers: UCSF Medical Center at Mount Zion, UCSF Medical Center at Mission Bay, UCSF Medical Center at Parnassus, Zuckerberg San Francisco General Hospital and Trauma Center, and the San Francisco Veterans Affairs Medical Center.
RAHUL AGGARWAL, MD  
Dr. Rahul Aggarwal is a specialist in cancers of the genital and urinary organs at the UCSF Helen Diller Family Comprehensive Cancer Center. He also serves as director of the UCSF STAND (Supportive Therapy in Androgen Deprivation) Clinic, which provides comprehensive care to men who are receiving androgen deprivation therapy, hormone therapy for prostate cancer.

As a member of the Developmental Therapeutics Genitourinary Cancer Program, Aggarwal enrolls patients with advanced solid tumor malignancies into early-phase clinical trials of novel targeted treatments. His research focuses on developing hormonal treatment strategies that reduce the toxicity of androgen deprivation therapy for men with advanced prostate cancer. He is also interested in developing new molecular imaging techniques that will help predict how advanced solid tumors will respond to treatment.

Aggarwal earned his medical degree from the Northwestern University Feinberg School of Medicine. At UCSF, he completed an internship and residency in internal medicine, followed by a clinical fellowship in hematology and oncology. Aggarwal has also been a research fellow in developmental therapeutics at Genentech. He is a member of the American Society of Clinical Oncology (ASCO) and a research fellow in biotechnology.  She joined the Prostate Cancer Program in 2016.

Hala Borno, MD  
Dr. Hala Borno is a medical oncologist at UCSF and an Assistant Professor in the Department of Medicine and Division of Hematology/Oncology. She has clinical expertise in the management of advanced urologic malignancies such as prostate, kidney, bladder, and testicular cancers, and cares for patients at the Helen Diller Family Comprehensive Cancer Center (HDFCCC) at UCSF. At HDFCCC, Dr. Borno serves on the executive leadership committee for the Prostate Cancer Program and the Liaison to the Office of Community Engagement. She is also a member of the American Society of Clinical Oncology Social Determinants of Health working group, GU committee for NRG oncology, and Health Disparities Committee for Alliance for Clinical Trials in Oncology.

Adina Bailey, PhD  
Adina Bailey, PhD serves as Program Manager for UCSF’s Prostate Cancer Program. She completed a BA in Molecular Biology at UC Berkeley and holds a doctoral degree in Biology (Molecular Genetics) from UC San Diego. She completed postdoctoral training at UC Berkeley as a Fellow of the Helen Hay Whitney Foundation. She has worked as a research scientist and manager with Howard Hughes Medical Institute and in biotechnology. She joined the Prostate Cancer Program in 2016.

PETE CARROLL, MD, MPH  
Dr. Peter Carroll is a Professor and Chair of the UCSF Department of Urology. He received his Medical Degree with Honors from Georgetown University School of Medicine, and came to UCSF for his general surgery training and urology residency. He completed a fellowship in urologic oncology at Memorial Sloan-Kettering Cancer Center and joined the UCSF Department of Urology in 1986.

Dr. Carroll organized the Urologic Oncology Service, one of the most active multidisciplinary programs at UCSF. In 1996 he assumed the Chair of the UCSF Department of Urology, consistently ranked as one of the top urology departments in the country by U.S. News and World Report. He holds the Ken and Donna Derr-Chevron Distinguished Professorship, and he served as surgeon-in-chief of the UCSF Comprehensive Cancer Center from 2003 through April 2007. In September 2006, Dr. Carroll became the Director of Strategic Planning and Clinical Services of the UCSF Helen Diller Family Comprehensive Cancer Center and Associate Dean, School of Medicine. In May 2008 he earned his MPH from UC Berkeley.

Dr. Carroll has authored or co-authored over 500 publications. He is now Past President of the American Board of Urology (2006-2008). He is currently principal or co-investigator on numerous scientific studies. His major professional interests are the study and management of urologic cancers, innovative methods of urinary tract reconstruction, health services research, health policy and the impact of cancer detection and treatment on quality of life.

Dr. Carroll was awarded the 2010 Eugene Fuller Triennial Prostate Award and the SUO Medal from the AUA and SUO, respectively. In 2014, he was also awarded the coveted Barringer Medal from the American Association of Genitourinary Surgeons. This award recognizes a younger member who is achieving “distinguished accomplishments.” In 2017, he accepted a position as AAGUS Treasurer. He is also the Taube Family Distinguished Professor in Urology Department of Urology.

Dr. Carroll is committed to reducing the burden of prostate cancer treatment—physical, psychological, and monetary. He pioneered and remains a vocal advocate for standardizing an active surveillance regimen in patients with low-volume, early stage prostate cancer. Active surveillance carefully determines which patients can safely postpone radical treatment while still maintaining an acceptably low risk of cancer progression. At the same time, by improving early prognostic capabilities, Dr. Carroll strives to identify which men may benefit from more aggressive early therapies.

JUNE CHAN, Sc.D  
Dr. June Chan earned her AB at Harvard College in applied mathematics, followed by a doctorate in science from the Harvard School of Public Health. She was a Fulbright Scholar in Sweden and completed a post-doctoral fellowship at the Department of Epidemiology at the Harvard School of Public Health. Dr. Chan received a CapCUR (now known as the Prostate Cancer Foundation) Young Investigator Award;
and was awarded the Steven and Christine Burd-Safeway Distinguished Professorship in 2009. Dr. Chan is a member of the UCSF Prostate Cancer Center.

Dr. June M. Chan has broad interests in cancer prevention and public health, in particular what individuals can do to modify their risk of chronic disease, co-morbidity, and death. She has expertise and interests in epidemiology and medical education; and has conducted research on diabetes, pancreatic, colon, and prostate cancer.

Dr. Chan’s current research is focused on understanding how diet, exercise, hormones, and genetics contribute to prostate cancer incidence, progression, and death. She is particularly interested in identifying modifiable lifestyle risk factors for prostate cancer progression, and using this information to help us better understand prostate cancer biology as well as inform public health guidelines. The goals of her clinical and translational research studies are to identify risk-reduction strategies for men with or at high risk for prostate cancer; evaluate novel molecular markers of prostate cancer aggressiveness that may improve screening, diagnosis, or prognosis of clinically relevant disease; and improve cancer survivorship for the millions of men living with prostate cancer worldwide.

She is PI of the prospective national Diet and Lifestyle Study within the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE), and a multi-site clinic-based cohort study examining nutritional and genetic risk factors for aggressive prostate cancer. She also collaborates with colleagues at the Harvard School of Public Health on the Health Professionals Follow-up Study to examine diet and lifestyle risk factors for prostate cancer progression, metastases, and death.

MATTHEW COOPERBERG, MD, MPH
Dr. Matthew Cooperberg received his undergraduate training from Dartmouth College, where he earned a degree in English with high honors. He then enrolled in Yale University’s MD, MPH program, concurrently earning an MPH with a concentration in Health Policy from the School of Epidemiology and Public Health, and a MD from the School of Medicine. He completed his General Surgery and Urology training at the University of California, San Francisco, and subsequently continued at UCSF to complete a fellowship in Urologic Oncology under the guidance of Peter Carroll, MD, MPH. In 2009, Dr. Cooperberg was recruited to join the faculty at UCSF and the San Francisco Veterans Affairs Medical Center. Specializing in urologic cancer care, he is part of the multidisciplinary urologic oncology team of the UCSF Helen Diller Family Comprehensive Cancer Center, located primarily at the Mission Bay campus. He also maintains privileges at San Francisco General Hospital. In 2013, Dr. Cooperberg received the first Helen Diller Family Chair in Urology and a secondary appointment in the Department of Epidemiology and Biostatistics. In 2015 he won the American Urological Association Gold Cystoscope Award, given annually to one urologist for contributions to the field in the first 10 years of practice, and was also named Young Urologist of the Year. He was named professor in 2018.

Dr. Cooperberg’s clinical interests include the early detection, diagnosis, and management of genitourinary malignancy, and using minimally invasive techniques to treat benign and malignant diseases. He performs robotic, laparoscopic, endoscopic, and percutaneous surgeries, and is interested in incorporating promising new technologies into his practice. He is particularly interested in risk-stratifying prostate, renal, and other tumors, and matching treatments appropriately to those patients most likely to benefit, using novel imaging tests and biomarkers together with clinical information. Dr. Cooperberg is a Fellow of the American College of Surgeons, and a member of the American Urological Association (AUA) and the Society for Urologic Oncology. In 2012. Dr. Cooperberg co-wrote a proposal to establish a national urology registry. From this proposal developed the AUA Quality (AQUA) Registry, a national database tracking practice patterns, quality of care, and both clinical and patient-reported outcomes for patients across the U.S. with prostate cancer and other urologic conditions. Dr. Cooperberg continues in a senior leadership role with the project.

Drawing on the CaPSURE registry, UCSF’s institutional databases, and other data resources, Dr. Cooperberg has written over 295 peer-reviewed scientific articles, and has been invited to present his research findings at many national and international conferences. His primary research focus is prostate cancer, with particular areas of interest including: 1) health services research, documenting ongoing trends and regional variation in the use of diagnostic, imaging, and therapeutic interventions for men with all stages of prostate cancer; 2) risk assessment and biomarker research, developing and validating prognostic tools incorporating both standard clinical information and emerging biomarkers; 3) comparative effectiveness research, examining evidence regarding the relative benefits of surgery, radiation, and other treatments in terms of cancer control, quality of life, and cost; and 4) decision support and survivorship, helping men make better-informed decisions about both treatments and management of short- and long-term treatment sequelae. He is also very interested in disparities in prostate cancer access and outcomes, and in prostate cancer as an international disease. He helped forge a number of inter-continental collaborations which are yielding fascinating insights into prostate cancer’s variation in presentation and outcome around the world. He has received numerous awards for his research papers and is co-investigator on multiple grants. He won a prestigious Young Investigator Award from the Prostate Cancer Foundation, and is a current investigator on a number of ongoing Federal grants including his first R01 as principle investigator, awarded in 2016 to study microRNAs as candidate prostate cancer biomarkers.

FELIX FENG, MD
Dr. Felix Feng, MD, received his undergraduate training from Stanford University, where he earned a degree in Biological Sciences and received a President’s Award for Academic Excellence. He then received his MD from Washington University in St. Louis, where he received numerous awards for his research and academic achievements. He then completed both a postdoctoral research fellowship and his residency in radiation oncology at the University of Michigan, and subsequently joined the faculty there. In addition to being the Director of the Division of Translational Genomics, Dr. Feng also co-led the multidisciplinary clinic for prostate cancer patients and served as Director of the Genitourinary Cancer Program within the Department of Radiation Oncology at the University of Michigan. In 2016, Dr. Feng was recruited to join the faculty at UCSF, where he (continued on next page)
FELIX FENG, MD, (continued)
currently is an Associate Professor of Radiation Oncology, Urology, and Medicine, and serves as Vice Chair for Faculty Development and Director of Translational Research for the Department of Radiation Oncology.

Dr. Feng’s clinical interests include the diagnosis and management of genitourinary malignancies. He specializes in the treatment of high-risk aggressive prostate cancers as well as oligometastatic disease. For upfront or post-surgical treatment for patients, his therapeutic approaches include intensity-modulated radiation therapy as well as stereotactic ablative radiotherapy, among many others. Dr. Feng is nationally known for his approaches of using molecular biomarkers to help guide or personalize radiation therapy for patients. He serves as the leader of the Genitourinary Cancer Translational Research Program for the NRG Clinical Trials Group, and is a member of the National Cancer Institute Steering Committee for Genitourinary Cancers. He has helped conduct numerous clinical trials, and is the co-principal investigator of one of the first biomarker-driven clinical trials for patients with metastatic prostate cancer.

Dr. Feng is a physician-scientist focused on clinical and translational research aimed at improving outcomes for patients with prostate cancer. His laboratory focuses on identifying and validating biomarkers associated with treatment resistance in prostate cancer patients, and overcoming radiation or hormone therapy resistance with targeted therapy. He has published over 130 peer-reviewed scientific articles, and his major contributions to the medical field include: 1) the development of novel molecular subtyping approaches to distinguish biological subgroups of prostate cancer that differ in treatment response, 2) identification of new drivers of aggressive prostate cancer; 3) the development of novel therapeutic approaches to treat prostate cancer. He has published manuscripts in leading journals such as the New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology, European Urology, Nature, and Nature Genetics. He has received numerous awards for his research and is the principal investigator on multiple grants, from various federal and foundation sources.

TOM HOPE, MD
Dr. Thomas Hope is a radiologist and nuclear medicine physician (an expert in medical applications of radioactive substances). He specializes in neuroendocrine tumors, with a focus on peptide receptor radionuclide therapy, which targets these cancer cells with a high dose of radiation. He has a special interest in molecular imaging and in treating cancer using the targeted, individualized techniques of precision medicine.

In addition to working with patients, Dr. Hope conducts research on novel radiopharmaceuticals, or new radioactive imaging substances that can help physicians locate tumors. He also works on combining different imaging modalities – such as positron emission tomography and MRI to stage cancer in patients.

Dr. Hope received his medical degree from Stanford University School of Medicine. He completed a residency in diagnostic radiology at UCSF. He then completed a fellowship in nuclear medicine and body MRI at Stanford.

Dr. Hope is a member of the Radiological Society of North America, Society of Nuclear Medicine and Molecular Imaging, Society of Abdominal Radiology and International Society for Magnetic Resonance in Medicine.

Stacey A. Kenfield, ScD
Stacey A. Kenfield, ScD received her Bachelor of Science from UCLA in Physiological Science, followed by a Master of Science in Epidemiology, a Doctor of Science in Epidemiology, and a post-doctoral fellowship, all completed at the Harvard T.H. Chan School of Public Health. She continues to lead the Harvard-based Health Professionals Follow-up Study (HPFS) prostate cancer clinical follow-up of more than 7,500 men with prostate cancer since assuming this role in 2005. These data are used to identify factors that may improve prognosis and quality of life. She has worked in cancer epidemiology for the past 10 years and received a Prostate Cancer Foundation Young Investigator Award in 2012. She was appointed as the Helen Diller Family Chair in Population Science for Urologic Cancer in 2016.

THOMAS KIRK
Tom Kirk has been heavily involved in Patient Advocacy Non-Profit Organizations. He currently serves as the volunteer Vice-President of the California Prostate Cancer Coalition (CPCC), which is “a proud participant” in the National Alliance of State Prostate Cancer Coalitions (NASPCC). CPCC is the co-presenter of this conference: The 2019 CPCC/UCSF Patient Conference on Prostate Cancer. Tom is also an Invited Member of the NASPCC Executive Committee.

Tom Kirk developed the Strategic Plan for NASPCC in 2017 and as Chair of NASPCC’s Steering Committee, he monitors the Plan’s implementation with the NASPCC Committees that were created to move it forward. Tom also serves on the NASPCC Advocacy and Public Policy Committee which, following NASPCC’s 2018 Bone Health Access Initiative (BHI), and the October Bone Health Access Roundtable, prioritized “Step Therapy” as an issue.

In prostate cancer, Tom served as the President and CEO of Us TOO International in suburban Chicago for over 10 years, before moving to California in 2016. He currently works as a Co-Founder of Informed Health Consulting (IHC). Additionally, Tom worked for over 12 years at the National Alzheimer’s Association headquartered in Chicago. He worked on the Senior Management Team where he was the Vice President of Patient, Family and Education Services. He has also assisted other Residential Care Providers (Mather Life Ways and Belmont Village) develop their Dementia Care Services, and he worked as the Vice President of Operations for Life Care Centers of America’s Garden Terrace Associates managing their specialized Dementia-Specific Long-Term Care Centers and Dementia Care Units. Tom holds an MSSW Degree in Planning and Administration from the University of Wisconsin-Madison.

MEREL GREY NISSENBERG, ESQ.
Merel Grey Nissenberg, Esq. is a medical malpractice attorney in Los Angeles handling cases around the country, and she is President of three non-profits in healthcare: the National Alliance of State Prostate Cancer Coalitions (NASPCC); the California Prostate Cancer Coalition (CPCC), both of which she co-founded; and the Clifton F. Mountain Foundation for Education & Research in Lung Cancer. She is a member of two National Cancer Institute SPORES (one in Prostate Cancer (continued on next page)
MEREL GREY NISSENBERG, ESQ. (continued)

at UCLA, one in Lung Cancer at M. D. Anderson Cancer Center), and she is on the UCLA SPORE Executive Committee. She is also the Advocate for the Canary Foundation/PASS Trial at Stanford (Prostate Active Surveillance) and is part of a PCORI Grant with UCLA dealing with decision aids in prostate cancer. Additionally, through her consulting group Informed Health Consulting she and her partner help accrue patients to Clinical Trials and also create Patient Ambassador Programs and Roundtables. Merel has been actively involved for almost ten years as one of three national Patient Advocates for the Early Detection Research Network (EDRN) of the National Cancer Institute, handling three of the four Collaborative Groups: GU Cancers, GYN Cancers, and Lung Cancer. In her law practice she has represented many cancer patients, and has advocated for them and for their families. Merel is extremely interested in the early detection of cancers when they are still curable and is dedicated to improving the lives of patients, including those as-yet-undiagnosed.

MICHAEL W. RABOW, MD, FAAAAHPM

Michael W. Rabow, MD, FAAAAHPM, the Helen Diller Family Chair in Palliative Care, is a Professor of Clinical Medicine and Urology and Associate Chief of Education & Mentoring in the Division of Palliative Medicine, Department of Medicine, at the University of California, San Francisco. Dr. Rabow attended UCSF for medical school and general internal medicine residency training. He completed fellowships at UCSF in general medicine, as well as in medical education research and is board-certified in internal medicine and hospice and palliative care. For 25 years previously, Dr. Rabow was in the Division of General Medicine and continued an active primary care practice along with his work in palliative care.

Dr. Rabow directs a leading outpatient palliative care program - the Symptom Management Service - at the UCSF Helen Diller Family Comprehensive Cancer Center. One of the largest palliative care programs in a cancer center nationally, the Symptom Management Service currently provides outpatient palliative care co-management in more than 30 half-day clinics weekly across three campuses at UCSF. He was the founding director of the UCSF/Mount Zion Hospital and Bakar Hospital Palliative Care Consultation Services.

Dr. Rabow is a national expert in outpatient palliative care research and service delivery. He has conducted both controlled and longitudinal trials of outpatient palliative care consultation, as well as multiple surveys of current outpatient palliative care consultation practices nationally. He is currently part of a PCORI study examining home-based palliative care. He lectures widely and has published over 60 papers in peer-reviewed journals in the areas of palliative care, spirituality, family caregiving, and end-of-life care education.

An expert in Community-Based Palliative Care, Dr. Rabow also serves as a consultant to medical centers nationally working to develop or expand their palliative care services, and as a consultant to numerous prominent professional or philanthropic organizations dedicated to expanding palliative care access and quality. Dr. Rabow served as the lead of the project advisory board for the “Improving Palliative Care in the Outpatient Setting” (IPAL-OP) initiative at the Center to Advance Palliative Care.

He directed the outpatient palliative care service assessment team for the National Comprehensive Cancer Network. Dr. Rabow is on the advisory board to the Palliative Care Institute of the California State University at San Marcos, which provides online education and certification for members of the palliative care interdisciplinary team.

Dr. Rabow is one of the leads of the UCSF Palliative Care Leadership Center (PCLC) and a member of the curriculum development committee for the PCLC Initiative nationally. The PCLC Initiative has trained more than 1000 hospital- and community-based palliative care programs in the United States. Previously, Dr. Rabow helped direct the California Hospital Initiative in Palliative Services, the first program to support the development of hospital-based palliative care services in California. In addition, Dr. Rabow served as a technical advisor and member of the leadership team for the Archstone Foundation's Hospital-Based Palliative Care Service Innovations project.

Dr. Rabow is the founding director of the Center for Education in Palliative Care at UCSF/Mount Zion, which also serves as the central hub for palliative care education across the UCSF enterprise. Dr. Rabow is an active member of the UCSF Academy of Medical Educators. He was Assistant Editor for the bimonthly section in the Journal of the American Medical Association entitled “Perspectives on Care at the Close of Life.” This series now appears as a palliative care textbook, Care at the Close of Life. For 15 years, he served as the Director of the Center for the Study of the Healer’s Art at the Institute for the Study of Health and Illness at Commonweal in California. Dr. Rabow is the Associate Editor of the world’s best-selling annually-updated general medicine textbook, Current Medical Diagnosis and Treatment. Dr. Rabow is the executive producer of “The Caregivers” documentary film and accompanying family caregiver handbook.

TIFFANY RAZZO

Tiffany Razzo currently works as the office manager for the Department of Genitourinary Medical Oncology at The University of Texas, MD Anderson Cancer Center in Houston, Texas. Prior to moving to Texas, Tiffany, a California native, worked at the Keck Medical Center of USC in Los Angeles where she was an office coordinator in the Department of Clinical Social Work for almost 5 years. Prior to that, Tiffany worked various healthcare jobs in various settings. In total, Tiffany has more than 15 years working in the healthcare field and says that her desire to help people get the care needed is what has kept her in healthcare this long.

Tiffany obtained her BS degree in Business Administration and MBA degree from Mount Saint Mary’s University, Los Angeles. Tiffany was also recently admitted to the Sigma Beta Delta International Honor Society for Business, Management, and Administration. Tiffany sits on the Board of Directors for the California Prostate Cancer Coalition as its Secretary and is honorary staff member for the National Alliance of State Prostate Cancer Coalitions. Tiffany is a uterine cancer survivor herself and understands the importance of early detection, education, and playing an active role in your health.
MACK ROACH III, MD

Dr. Mack Roach III is a radiation oncologist and an internationally renowned expert on treating and managing prostate cancer. Dr. Roach is a Professor of Radiation Oncology, Medical Oncology and Urology, at the University of California, San Francisco. He earned his MD from Stanford University School of Medicine. Dr. Roach has gained international recognition as an authority on treatment planning for prostate cancer and served as senior author for the guidelines for treatment planning recently published by the American College of Radiology. He is a member of several professional societies including the American Society of Clinical Oncology, American Society for Therapeutic Radiology and Oncology, Radiation Therapy Oncology Group, the NCI IMRT Working Group and American Joint Commission for Cancer (AJCC) Staging (GU), the American Cancer Society (ACS) Task for Cancer Screening Guidelines (Prostate cancer) and the NCI Concept Evaluation Panel (Prostate Cancer Phase III Trials).

Dr. Roach’s major research interest involves the application of 3-D conformal and intensity modulated radiotherapy (IMRT) as a major component of combined modality management of prostate cancer and other solid tumors. Over the last 12 years his research efforts have been directed at defining optimal imaging modalities, criteria for target definitions, development of improved treatment techniques, as well as the prediction of complication probabilities. This work has found expression in the Clinical Trials Cooperative Group Mechanism. He chaired a large prospective randomized trial comparing different strategies for locally advanced prostate cancer.

Dr. Roach has gained recognition as an authority on treatment planning for prostate cancer and served as senior author for the guidelines for treatment planning, recently published by the American College of Radiology. He has begun to pioneer intensity modulated radiotherapy (IMRT), in combination with Online Portal Imaging, and improved dose calculation algorithms that should allow UCSF Radiation Oncology to provide leadership in the field of radiotherapy for many years to come. Roach is considered a foremost authority in disparities in outcomes from cancer treatment in underserved populations. A recently funded NIH U-56 cooperative planning grant with San Francisco State University should allow both institutions to build a program to effectively address this area in years to come.

ALAN SHINDEL, MD

Dr. Alan W. Shindel is a urologist who specializes in sexual function and dysfunction, testosterone biology, urinary disorders in men and chronic pelvic pain syndromes. Dr. Shindel’s research interests include medical student education, sexual wellness and new methods for assessing bladder and pelvic pain conditions.

Dr. Shindel earned his medical degree and completed a residency in urology at Washington University School of Medicine in St. Louis. He completed a fellowship in andrology – men’s health – at UCSF. He then earned a master of advanced study degree in clinical research at the University of California, Davis.

Dr. Shindel is an associate editor of the Journal of Sexual Medicine, and serves on the Sexual Medicine Society of North America’s executive board and on the male sexual dysfunction guidelines panel for the American Urological Association. He is also on the admissions committee for UCSF School of Medicine.

STAN ROSENFELD

Stan Rosenfeld was diagnosed with prostate cancer in 1997. He became an expert meta-researcher, and now, believing that knowledge is power, he has dedicated himself to educating men on how to reduce their risk of getting prostate cancer, the importance of early detection, and the importance of guidance through the decision process with a diagnosis of prostate cancer.

Stan Rosenfeld chairs UCSF’s Urology Patient Services Committee, and has been a long-time patient advocate for UCSF. He is also a Member of UCSF’s Prostate Cancer Leadership Program. He is a charter participant in UCSF’s Peer-to-Peer Program which offers one-on-one help for men with prostate cancer; and serves on the UCSF Patient and Family Advisory Council.

Mr. Rosenfeld serves on the Executive Board of Directors of the California Prostate Cancer Coalition (CPCC), a not-for-profit 501(c)(3) organization formed in 1997. CPCC is the co-presenter of this conference: The 2019 CPCC/UCSF Patient Conference on Prostate Cancer. He has led CPCC’s Best Practices Workshops for Support Group Leaders yearly in Northern and Southern California since 2000.

Stan Rosenfeld is a member of the Prostate Cancer Panel for the National Comprehensive Cancer Network (NCCN). He is also a Member of the Oncology Committee of Marin General Hospital and a Member of the Marin General Hospital Patient and Family Advisory Council.

Stan Rosenfeld has been facilitating a weekly support group for men with prostate cancer at Marin General Hospital since 2000. He is a member of the US TOO International Help Desk. Stan is especially interested in Quality of Life issues and is working on several projects in the area of treatment decisions.

ERIC J. SMALL, MD, FASCO

Eric J. Small, MD, is a professor of medicine and urology at the University of California, San Francisco, where he is the leader of the Prostate Cancer Program, and Deputy Director and Chief Scientific Officer in the Helen Diller Family Comprehensive Cancer Center. His patient care and research is focused on prostate cancer, immunotherapy and the mechanisms of resistance to standard therapies, most recently focusing on the development of treatment associated small cell/neuroendocrine prostate cancer (t-SCNC).

Dr. Small was principal investigator for the Stand Up To Cancer West Coast Prostate Cancer Dream Team, and has been involved with the development of a number of therapeutics including abiraterone, apalutamide, sipuleucel T, and ipilimumab. Dr. Small is a member of the Board of Directors of the American Society of Clinical Oncology (ASCO).

Dr. Small earned a bachelor’s degree from Stanford University and a medical degree from Case Western Reserve University School of Medicine. While in medical school, he completed a fellowship in pathology. He completed post-graduate residency training in internal medicine at Beth Israel Hospital (Boston) and a fellowship in hematology and oncology at UCSF before joining the UCSF faculty.
THE CALIFORNIA PROSTATE CANCER COALITION RECOMMENDS THAT YOU TAKE CHARGE!

• Become knowledgeable about your health and about prostate cancer
• Encourage all men to have a PSA and a DRE at the appropriate ages and intervals
• Keep a written record of your PSA levels to observe any changes
• Encourage and adopt healthy lifestyle changes to reduce risk and for better cancer outcomes
  - Add more fruits and vegetables to your diet and replace animal protein
  - Vitamin D, green tea and tomato products may reduce prostate cancer risk
  - Eat more whole grains and legumes
  - Exercise
  - Reduce stress
• Know your family medical history
• Join a Support Group!
• Spread the word about Informed Decision-Making and distribute our Informed Decision-Making Laminate when possible
• Advocate for the early diagnosis and treatment of potentially deadly prostate cancer
• Learn about clinical trials for cancer patients
• Participate in outreach programs and help spread the word about Early Detection
• Become an advocate for lessening the burden of prostate cancer

CPCC CAN HELP YOU:

• Find your local support group
• Find others who share your diagnosis
• Find a place to turn for help when you have been diagnosed
• Find links to other resources
• Keep up to date on prostate cancer news and other information
• Become informed and aware
WE WOULD LIKE TO THANK OUR SPONSORS FOR SUPPORTING THIS CONFERENCE!